EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis

Mehrzad Mirzania, Fatemeh Anari, Seyed Amir Hossein Emami, Kamran Roudini, Mehdi Karimi iD, Kianmehr Saleh, Masoud Mortezazadeh iD, Ahmad Khajeh-Mehrizi iD

International Journal of Breast Cancer · 2026-01 · 2026 (1)

DOI: 10.1155/ijbc/6630563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Breast Cancer, online erschienen am 19.06.2026. Verfasst von Mehrzad Mirzania und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran,…. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Locally advanced breast cancer (LABC) remains a major therapeutic challenge, with neoadjuvant chemotherapy (NAC) serving as a cornerstone of management. However, direct evidence comparing the efficacy of sequential (AC‐T) and concurrent (TAC) anthracycline–taxane regimens in real‐world Middle Eastern populations remains scarce. This study is aimed at comparing the clinical outcomes of AC‐T and TAC in Iranian women with LABC.

Methods

A retrospective cohort study was conducted among 118 patients with Stage III breast cancer treated at Tehran, Iran. Patients received either AC‐T (doxorubicin/cyclophosphamide followed by paclitaxel; n = 70) or TAC (docetaxel/doxorubicin/cyclophosphamide; n = 48). Outcomes included pathological complete response (pCR), overall survival (OS), disease‐free survival (DFS), distant recurrence‐free survival (DRFS), and locoregional recurrence‐free survival (LRFS).

Results

Baseline demographic and clinical characteristics were comparable between groups. No significant difference in pCR rates was observed between the groups. The AC‐T regimen showed higher, though nonsignificant, OS at 3, 5, and 10 years (90%, 82%, and 71%, respectively) compared with TAC (83%, 74%, and 57%). Conversely, TAC demonstrated significantly superior 10‐year DRFS (62% vs. 45%, p = 0.019). DFS and LRFS were similar between regimens. Multivariable Cox regression analysis identified ER positivity as the only independent predictor of improved OS (HR = 0.42, 95% CI: 0.29–0.82, p = 0.012) and DFS (HR = 0.36, 95% CI: 0.18–0.73, p = 0.005), whereas the chemotherapy regimen was not independently associated with survival after adjustment for confounders.

Conclusion

Both AC‐T and TAC provided effective neoadjuvant control in LABC, with comparable survival outcomes. These findings support individualized regimen selection based on patient profile and tumor biology. Prospective studies are needed to refine region‐specific treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

anthracycline-taxane regimensbreast cancermetastasisneoadjuvant chemotherapyoncologypathologic complete responsesurvival

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
  • Faculty of Medicine, Bogomolets National Medical University (NMU), Kyiv, Ukraine.
  • Cancer Research Center, Hamadan University of Medical Science (UMSHA), Hamadan, Iran.

ORCID-Profile: Mehdi Karimi, Masoud Mortezazadeh, Ahmad Khajeh-Mehrizi

Zitieren

APA

Mirzania, M., Anari, F., Emami, S. A. H., Roudini, K., Karimi, M., Saleh, K., Mortezazadeh, M., & Khajeh-Mehrizi, A. (2026). Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis. International Journal of Breast Cancer, 2026(1). https://doi.org/10.1155/ijbc/6630563

Vancouver

Mirzania M, Anari F, Emami SAH, Roudini K, Karimi M, Saleh K, et al. Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis. International Journal of Breast Cancer. 2026;2026(1). doi:10.1155/ijbc/6630563

BibTeX
@article{Mirzania2026,
  author = {Mirzania, Mehrzad and Anari, Fatemeh and Emami, Seyed Amir Hossein and Roudini, Kamran and Karimi, Mehdi and Saleh, Kianmehr and Mortezazadeh, Masoud and Khajeh-Mehrizi, Ahmad},
  title = {Efficacy of AC‐T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis},
  journal = {International Journal of Breast Cancer},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijbc/6630563}
}
Kostenlos starten →